The case report of a 56-year-old patient diagnosed with recurrent GBM who was given second-generation CAR-T cells therapy with a 4-1BB co-stimulatory domain targeting B7-H3 dates back to 2021. The gene discussed is CD276; the disease is glioblastoma.